issued
on 12 Dec 2023
Last Applicant/ Owned by
3800 Paramount Parkway, Suite 100
Morrisville
NC
27560
Serial Number
97533863 filed on 03rd Aug 2022
Registration Number
N/A
Correspondent Address
Margarita Wallach, Esq.
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Contract research organization (CRO) services, namely, monitoring of clinical trials for drugs, biologics and devices of pharmaceutical, medical, healthcare, and life sciences companies for quality control purposes, and clinical trial project management in the nature of design and implementation of clinical trials and quality assurance for all major therapeutic areas, in particular gastroenterologRead More
Providing independent review of clinical trials involving human subjects, namely, reviewing research protocols and related information to ensure protection of the rights and welfare of human subjects of research; regulatory compliance consulting in the pharmaceutical, medical, healthcare, and life sciences fields
Contract research organization (CRO) services, namely, monitoring of clinical trials for drugs, biologics and devices of pharmaceutical, medical, healthcare, and life sciences companies for quality control purposes, and clinical trial project management in the nature of design and implementation of clinical trials and quality assurance for all major therapeutic areas, in particular gastroenterology, nephrology, urology, and oncology; consulting services in the field of scientific research in the nature of conducting clinical trials in the pharmaceutical industry, the biotechnology industry and the medical device and diagnostics industries; providing quality assurance services in the field of regulatory submissions to the FDA by life sciences companies to ensure validity and accuracy; product development for others, namely, providing implementation services relating to the development and validation of drugs, biologics and medical devices; Software as a service (SaaS) services featuring software for accessing, collecting, managing, tracking, analyzing, and reporting data and information on clinical trials; Contract research organization (CRO) services, namely, custom technical writing for others for non-advertising purposes in the nature of medical writing of clinical study protocols and reports; Contract research organization (CRO) services, namely, custom writing for others for non-advertising purposes in the nature of medical writing of clinical study protocols and reports for submission to regulatory authorities
Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of pharmaceutical, medical, healthcare, and life sciences companies to assist them with clinical research, clinical trials and applications for drug, biologic and device approval; providing independent review of clinical trials for business purposes; Contract research organization (CRO) services, namely, business management in the field of clinical trials, namely, clinical data management
No 97533863
No Service Mark
No 137232/00010
No
No
No
No
No
No
No
No
24.17.12 -
Infinity symbol
27.01.04 -
Letters or numerals, including punctuation, forming representations of objects, parts of objects, or maps
27.03.05 -
Representations of objects forming letters or numerals, including punctuation
The mark consists of the stylized wording "CAIDYA" with the stylized letters "C" and "A" intertwined together to form an infinity symbol.
| Status Date | Action Taken |
|---|---|
| 12th Dec 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 17th Oct 2023 | PUBLISHED FOR OPPOSITION |
| 17th Oct 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 27th Sep 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 07th Sep 2023 | EXAMINERS AMENDMENT -WRITTEN |
| 07th Sep 2023 | EXAMINERS AMENDMENT E-MAILED |
| 07th Sep 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| 07th Sep 2023 | EXAMINER'S AMENDMENT ENTERED |
| 07th Sep 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 01st Sep 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
